Beyondspring (BYSI) PT Set at $60.00 by HC Wainwright
Beyondspring (NASDAQ:BYSI) received a $60.00 target price from equities researchers at HC Wainwright in a report released on Thursday. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 179.07% from the company’s previous close.
BYSI has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Beyondspring from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Maxim Group set a $52.00 price target on shares of Beyondspring and gave the company a “buy” rating in a report on Thursday, December 14th. Finally, Seaport Global Securities initiated coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They issued a “buy” rating and a $56.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Beyondspring currently has a consensus rating of “Buy” and an average price target of $54.50.
Beyondspring (NASDAQ:BYSI) opened at $21.50 on Thursday. Beyondspring has a twelve month low of $16.55 and a twelve month high of $48.49.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/03/03/beyondspring-bysi-pt-set-at-60-00-by-hc-wainwright.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.